1. South Korea Stocks

  2. •

    Industrials

  3. •

    Industrial - Machinery
Aprogen Medicines Inc.

Aprogen Medicines Inc.

007460.KS
Aprogen Medicines Inc.KR flagKorea Exchange
3,320.00
KRW
-100.00
- -
4.66BMarket Cap

Total Valuation

Aprogen Medicines Inc. carries a market capitalization of 4.66B, placing it among publicly traded companies globally. Its enterprise value stands at 1.82T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.66B
Enterprise Value1.82T

Share Statistics

Aprogen Medicines Inc. currently has 20.57M shares outstanding.

Shares Outstanding20.57M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 10.83, and the price-to-book ratio stands at -4.00.

PE RatioN/A
PS Ratio10.83
PB Ratio-4.00
P/TBV Ratio4.50
P/FCF Ratio-37.35
P/OCF Ratio-20.82

Enterprise Valuation

EV / Sales14.26
EV / EBITDAN/A
EV / EBITN/A
EV / FCF299.61

Financial Position

Aprogen Medicines Inc. maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.43, indicating elevated leverage, while an interest coverage ratio of 4.36 demonstrates adequate ability to service its debt obligations.

Current Ratio0.85
Quick Ratio0.21
Debt / Equity43.43
Debt / EBITDA-2.00
Interest Coverage4.36

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-10.70
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.50

Taxes

Income Tax-2.15B
Effective Tax RateN/A

Stock Price Statistics

Aprogen Medicines Inc.'s stock has declined approximately -97.84168% over the past 52 weeks. The 50-day moving average sits at 4,474.01, while the 200-day moving average is 8,202.69.

Beta (5Y)N/A
52-Week Price Change-97.84168%
50-Day Moving Average4,474.01
200-Day Moving Average8,202.69
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Aprogen Medicines Inc. generated 127.54B in revenue and converted that into -73.27B in net income, yielding earnings per share of -7,013.28. EBITDA reached -93.70B, while operating income came in at -93.70B.

Revenue127.54B
Gross Profit34.18B
Operating Income-93.70B
Pretax Income-140.71B
Net Income-73.27B
EBITDA-93.70B
EBIT-93.70B
Earnings Per Share (EPS)-7,013.28

Balance Sheet

Aprogen Medicines Inc. holds 40.46B in cash and equivalents against 187.09B in total debt, resulting in a net debt position of 151.04B. Total book value stands at -345.57B, with working capital of -29.99B providing operational flexibility.

Cash & Cash Equivalents40.46B
Total Debt187.09B
Net Debt151.04B
Equity (Book Value)-345.57B
Book Value Per Share-17,491.08
Working Capital-29.99B

Cash Flow

Aprogen Medicines Inc. produced -66.36B in operating cash flow over the past twelve months. After subtracting -29.36B in capital expenditures, free cash flow totaled -95.72B - equivalent to -4,845.01 per share.

Operating Cash Flow-66.36B
Capital Expenditures-29.36B
Free Cash Flow-95.72B
FCF Per Share-4,845.01

Margins

Aprogen Medicines Inc. operates with a gross margin of 26.80, reflecting its pricing power and cost economics. The operating margin of -73.47 and net profit margin of -57.45 provide insight into operational efficiency.

Gross Margin26.80
Operating Margin-73.47
Pretax Margin-110.32
Profit Margin-57.45
EBITDA Margin-73.47

Dividends & Yields

The company's payout ratio of -NaN indicates the proportion of earnings distributed to shareholders.

Dividend Per Share-NaN
Dividend YieldN/A
Payout Ratio-NaN
Shareholder Yield-3.10
FCF Yield-2.68

Stock Splits

Aprogen Medicines Inc.'s most recent stock split took place on May 8, 2026 with a 15:1 split ratio.

Last Split Date5/8/2026
Split Ratio15:1

Scores

Aprogen Medicines Inc. posts an Altman Z-Score of 1.49, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.49